The International Generic and Biosimilar medicines Association (IGBA) remains committed to its vision of working to improve patient access to safe, effective, cost-effective, and quality-assured generic and biosimilar medicines.

The 3rd Bioequivalence Conference, co-hosted by the International Generic and Biosimilar Medicines Association (IGBA) and Medicines for Europe, concluded today at the Hilton Amsterdam Airport Schiphol Hotel, The Netherlands. This landmark event brought together experts from regulatory authorities, industry, and academia to discuss the evolving bioequivalence landscape and its critical role in improving global access to medicines. 

The International Generic and Biosimilar Medicines Association (IGBA) in line with its goals of promoting the widest possible access to safe, effective, and quality-assured medicines; and of promoting intellectual property regimes which foster innovation and allow the timely entry of generic and biosimilar medicines, has released its report called “GAMING THE SYSTEM- An overview of originator companies’ evergreening strategies used to hinder access to generic and biosimilar products”.